Director Linney Yvonne sold 20,000 shares of Bionano Genomics Inc. [BNGO]

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Bionano Genomics Inc. shares valued at $72,402 were sold by Linney Yvonne on Aug 15. At $3.62 per share, Linney Yvonne sold 20,000 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Also, BARKER DAVID L purchased 10,000 shares, netting a total of over 16,000 in proceeds. Following the buying of shares at $1.60 each, the insider now holds 13,894 shares.

Before that, Holmlin R. Erik had added 5,025 shares to its account. In a trade valued at $20,037, the President and CEO bought Bionano Genomics Inc. shares for $3.99 each. Upon closing the transaction, the insider’s holdings increased to 5,025 shares, worth approximately $10150.5.

Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in mid June. As of September 24, 2020, Ladenburg Thalmann has initiated its “Buy” rating for BNGO. Earlier on April 08, 2020, Oppenheimer initiated its rating. Their recommendation was “an Outperform” for BNGO stock.

Analyzing BNGO’s Price Performance

On Wednesday, Bionano Genomics Inc. [NASDAQ: BNGO] plunged -5.16% to $2.02. The stock’s lowest price that day was $2.01, but it reached a high of $2.16 in the same session. During the last five days, there has been a drop of approximately -14.04%. Over the course of the year, Bionano Genomics Inc. shares have dropped approximately -32.44%. Shares of the company reached a 52-week high of $4.35 on 08/11/22 and a 52-week low of $1.16 on 05/12/22. A 50-day SMA is recorded $2.34, while a 200-day SMA reached $2.18. Nevertheless, trading volume fell to 5.48 million shares from 3.58 million shares the previous day.

Support And Resistance Levels for Bionano Genomics Inc. (BNGO)

According to the 24-hour chart, there is a support level at 1.97, which, if violated, would cause prices to drop to 1.91. In the upper region, resistance lies at 2.12. The next price resistance is at 2.21. RSI (Relative Strength Index) is 37.14 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.21, which suggests the price will decrease in the coming days. Percent R is at 98.21%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Bionano Genomics Inc. subject to short interest?

Stocks of Bionano Genomics Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 6.12 million shares to 44.17 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 38.05 million shares. A jump of 13.86% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.55 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.55.

Which companies own the most shares of Bionano Genomics Inc. (BNGO)?

According to BlackRock Fund Advisors filings, the company currently owns 17,794,958 shares, which is about 6.13% of the total BNGO shares outstanding. The investor’s shares have appreciated by 1,378,713 from its previous 13-F filing of 16416245.0 shares. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $37,616,442. SSgA Funds Management, Inc. acquire a 8.94% interest valued at $20.87 million while Geode Capital Management LLC purchased a 759,520 stake. A total of 3,548,719 shares of Bionano Genomics Inc. were bought by Renaissance Technologies LLC during the quarter, and 985,346 were bought by Morgan Stanley & Co. LLC. In its current portfolio, Northern Trust Investments, Inc. holds 2,629,841 shares valued at $6.52 million.

In terms of Bionano Genomics Inc. share price expectations, FactSet research, analysts set an average price target of $8.67 in the next 12 months, up nearly 275.59% from the previous closing price of $2.13. Analysts anticipate Bionano Genomics Inc. stock to reach $12.00 by 2022, with the lowest price target being $6.00. In spite of this, 3 analysts ranked Bionano Genomics Inc. stock as a Buy at the end of 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here